University of Pennsylvania

Sapient Appoints Jonathan Usuka as Chief Business Officer

Retrieved on: 
화요일, 5월 7, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, University, Informatics, Protein, University of Pennsylvania, McKinsey & Company, NIH, AI, Princeton University, Proteomics, MD, Doctor of Philosophy, Roche, Therapy, Stanford University, Patient, Genome, MBA, Drug development, Metabolomics, Drug discovery, Analytics, Celgene, Growth

Sapient , a leading biomarker discovery organization providing at scale services for multi-omics data generation and analysis, has announced the appointment of Jonathan Usuka, PhD, MBA as Chief Business Officer, expanding its leadership team to support and further propel the company’s rapid growth.

Key Points: 
  • Sapient , a leading biomarker discovery organization providing at scale services for multi-omics data generation and analysis, has announced the appointment of Jonathan Usuka, PhD, MBA as Chief Business Officer, expanding its leadership team to support and further propel the company’s rapid growth.
  • “We are absolutely thrilled to welcome Jonathan into this critical leadership role for Sapient,” said Mo Jain, MD, PhD, Founder and CEO of Sapient.
  • Previously, Dr. Usuka was a Senior Expert at McKinsey & Company, leading their Center for Analytics and Real-world Evidence.
  • “Sapient has an amazing group of scientists and a technology approach that can revolutionize the discovery and development of novel therapeutics, and I'm honored to join in that pursuit,” said Dr. Usuka.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

Retrieved on: 
수요일, 5월 8, 2024
Physician, University, PFA, EP, PRA, B cell, University of Pennsylvania, Cleveland Clinic, American Medical Association, St Davids, Patient, Arrhythmia, Multimedia, UCLA Health, Medical Center, Electrophysiology

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Participants included practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias—a condition in which the heart beats with an irregular or abnormal rhythm.
  • The primary teaching tool was live cases with expert commentary broadcast from the Electrophysiology Center at St. David's Medical Center, the leading robotic electrophysiology center in North America.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/texas-cardiac-arrhythmia-instit...
    SOURCE Texas Cardiac Arrhythmia Institute at St. David’s Medical Center

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias

Retrieved on: 
수요일, 5월 8, 2024
Physician, University, PFA, EP, PRA, B cell, University of Pennsylvania, Cleveland Clinic, American Medical Association, St Davids, Patient, Arrhythmia, UCLA Health, Medical Center, Electrophysiology

AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, May 8, 2024 /PRNewswire/ -- On April 18-19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Participants included practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias—a condition in which the heart beats with an irregular or abnormal rhythm.
  • The primary teaching tool was live cases with expert commentary broadcast from the Electrophysiology Center at St. David's Medical Center, the leading robotic electrophysiology center in North America.
  • Physicians received a maximum of 14.5 American Medical Association (AMA) Physician's Recognition Award (PRA) Category 1 Credit™ hours at the conference.

Universal Media Inc. Promotes Kyle Cook to President/Chief Strategy Officer

Retrieved on: 
금요일, 5월 3, 2024
University, Courage, University of Pennsylvania, UMI, Division 1, EVP, Partnership, Universal Sports, Media strategy, York College, Acquisition, Marketing, MBA, Knowledge, Management

MECHANICSBURG, Pa., May 3, 2024 /PRNewswire/ -- Anne Carnathan, President & CEO of Universal Media, Inc. (UMI) and Universal Sports & Entertainment (USE), is proud to announce the promotion of Kyle Cook to President/Chief Strategy Officer effective May 1, 2024.

Key Points: 
  • MECHANICSBURG, Pa., May 3, 2024 /PRNewswire/ -- Anne Carnathan, President & CEO of Universal Media, Inc. (UMI) and Universal Sports & Entertainment (USE), is proud to announce the promotion of Kyle Cook to President/Chief Strategy Officer effective May 1, 2024.
  • Formerly EVP of Media Strategy, Cook first joined the UMI team in 2011 as Sales Coordinator.
  • In his new role, Cook will lead the diversification of innovative media and data offerings, while overseeing agency alignment and supporting the professional growth of all employees.
  • "We look forward to our continued partnership with UMI and Kyle Cook as he shifts into his new role as president.

STUDENTS FROM MORE THAN 50 UNIVERSITIES ACROSS THE UNITED STATES SEND LETTER TO CONGRESS REQUESTING CONGRESSIONAL INTERVENTION TO STOP "TSUNAMI" OF ANTISEMITISM SWEEPING AMERICAN COLLEGE CAMPUSES

Retrieved on: 
금요일, 5월 3, 2024
Minority leader, Congress, Organization, Administration, University, University of Pennsylvania, Learning, Social media, George Washington University, Deportation, House, Columbia University, Student, Freedom, Speech, Violence, Exercise, Propaganda, Faculty, Face, Representative, Minority, Immunity, Terror, Letter, Democrat, ROCC, Management

Students from more than 50 universities signed the letter, citing inaction by university leadership in the face of escalating incitement to violence, threats, and harassment of Jewish students.

Key Points: 
  • Students from more than 50 universities signed the letter, citing inaction by university leadership in the face of escalating incitement to violence, threats, and harassment of Jewish students.
  • ROCC's mission is to restore college campuses to being safe environments for learning, intellectual inquiry, and freedom of expression, where all students are included and welcomed.
  • The antisemitism that is infecting our campuses does not distinguish between Republicans, Democrats, or Independents.
  • "As students and as Americans, we embrace and revere the right to free speech and expression—even when the speech is uncomfortable.

Supporting Pets in Their Fight Against Cancer: Petco Love Invests Additional $1 Million in May Pet Cancer Campaign

Retrieved on: 
수요일, 5월 1, 2024
Education, Texas A&M University, School, University, LSU, Nursing care plan, Mouth, Cancer, University of Pennsylvania, Partner, Pet, Virginia Tech Foundation, Ohio State University, Death, Love, Partnership, Research, Parent, Life, Cat, Disease, Veterinary medicine, Family, Louisiana State University, Diagnosis, Dog, SAN, UC

SAN ANTONIO, May 1, 2024 /PRNewswire/ -- Millions of pets and pet parents are impacted every year by pet cancer. National nonprofit Petco Love, in partnership with Blue Buffalo, continue their 14-year commitment to support treatment for pets fighting the disease, further pet cancer research, and raise awareness about early detection of pet cancer. Together, since 2010, their investment to fight pet cancer totals $20 million during this annual May Pet Cancer Campaign.

Key Points: 
  • National nonprofit Petco Love , in partnership with Blue Buffalo, continue their 14-year commitment to support treatment for pets fighting the disease, further pet cancer research, and raise awareness about early detection of pet cancer.
  • Together, since 2010, their investment to fight pet cancer totals $20 million during this annual May Pet Cancer Campaign.
  • Neva was able to receive lifesaving surgery and treatment thanks to the Petco Love and Blue Buffalo Pet Cancer Treatment Fund.
  • Anyone can also join the fight against pet cancer with Petco Love and help improve access to pet cancer treatment for pets and their families by donating at petcolove.org/pca .

WORLD INSURANCE ASSOCIATES NAMES KEN BOND AS NEW CHIEF CORPORATE DEVELOPMENT OFFICER

Retrieved on: 
화요일, 4월 30, 2024
University, Creighton University, Nuclear engineering, University of Pennsylvania, United, Commercial, Insurance, Cetera Financial Group, Aon (company), Navy, Bond, Nuclear Power School, SVP, Acquisition, Cetara, Genstar Capital, Management

ISELIN, N.J., April 30, 2024 /PRNewswire/ -- World Insurance Associates LLC (World), one of the fastest growing insurance brokerages in the U.S., announced today that Ken Bond has joined World as its new chief corporate development officer.

Key Points: 
  • ISELIN, N.J., April 30, 2024 /PRNewswire/ -- World Insurance Associates LLC (World), one of the fastest growing insurance brokerages in the U.S., announced today that Ken Bond has joined World as its new chief corporate development officer.
  • As an integral part of World's executive leadership team, Bond is responsible for overseeing corporate development for all three of World's businesses including retail insurance, retirement plan and wealth management services and wholesale insurance.
  • "I am thrilled to have an industry leader like Ken join our talented team," said Rich Eknoian, chief executive officer of World.
  • "It is extremely exciting to join World during this time of explosive growth across all of its businesses," said Ken Bond, World's chief corporate development officer.

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Retrieved on: 
목요일, 4월 25, 2024
Neuro-Oncology (journal), University, University of Pennsylvania, Abstract, Survival, ICI, CADL, ASCO, Lung cancer, Dana–Farber Cancer Institute, Patient, Society, MPH, Harvard Medical School, Clinical trial, Annual general meeting, Associate, Therapy, NSCLC, Valaciclovir, Injection, Pharmaceutical industry

NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL.

Key Points: 
  • NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL.
  • The first presentation will feature data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma.
  • Presenter: Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
    Full abstracts will be released by ASCO on Thursday, May 23, 2024, at 5:00 PM ET.
  • Details from the presentations will be available following the events on the Candel website at https://www.candeltx.com/media/ .

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Retrieved on: 
화요일, 4월 16, 2024
University, Cancer, Organic chemistry, University of Pennsylvania, AI, Merck & Co., Johnson & Johnson, Data science, Najat, Doctor of Philosophy, Research, Artificial intelligence, Entrepreneurship, Science, Patient, Chemistry, Biology, Ethics, Colgate University, Drug discovery, Committee, Economics, Computational chemistry, Pharmaceutical industry

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.

Key Points: 
  • SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
  • Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities.
  • “Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion.
  • Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) – a cross industry forum dedicated to driving impact through Data Science.

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

Retrieved on: 
금요일, 4월 26, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, School, University, Global Oncology, Cancer, Wastewater treatment, University of Pennsylvania, Pharmacovigilance, Incyte, Hematology, GSK plc, Drug, Partnership, MPM, Senior, Patient, Therapy, Head

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024.
  • “On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare into the leading precision oncology company that it is today.
  • "I look forward to the ongoing advancement of Repare’s pipeline and its continued progress as a leading precision oncology company."
  • Dr. Stein also previously served on the board of directors of Kura Oncology, Inc. from 2017 until May 2023.